Nishiyama Shoko, Ikegami Tetsuro
Department of Pathology, The University of Texas Medical Branch at Galveston, Galveston, TX USA.
Department of Pathology, The University of Texas Medical Branch at Galveston, Galveston, TX USA ; Sealy Center for Vaccine Development, The University of Texas Medical Branch at Galveston, Galveston, TX USA ; Center for Biodefense and Emerging Infectious Diseases, The University of Texas Medical Branch at Galveston, Galveston, TX USA.
Front Microbiol. 2015 Aug 11;6:787. doi: 10.3389/fmicb.2015.00787. eCollection 2015.
Rift Valley fever (RVF) is a mosquito-borne zoonotic disease endemic to the African continent. RVF is characterized by high rate of abortions in ruminants and hemorrhagic fever, encephalitis, or blindness in humans. RVF is caused by the Rift Valley fever virus (RVFV: genus Phlebovirus, family Bunyaviridae). Vaccination is the only known effective strategy to prevent the disease, but there are no licensed RVF vaccines available for humans. A live-attenuated vaccine candidate derived from the wild-type pathogenic Egyptian ZH548 strain, MP-12, has been conditionally licensed for veterinary use in the U.S. MP-12 displays a temperature-sensitive (ts) phenotype and does not replicate at 41°C. The ts mutation limits viral replication at a specific body temperature and may lead to an attenuation of the virus. Here we will review well-characterized ts mutations for RNA viruses, and further discuss the potential in designing novel live-attenuated vaccines for RVF.
裂谷热(RVF)是一种由蚊子传播的人畜共患病,在非洲大陆流行。裂谷热的特征是反刍动物流产率高,以及人类出现出血热、脑炎或失明。裂谷热由裂谷热病毒(RVFV:白蛉病毒属,布尼亚病毒科)引起。接种疫苗是预防该疾病唯一已知的有效策略,但目前尚无获批用于人类的裂谷热疫苗。一种源自野生型致病性埃及ZH548株的减毒活疫苗候选株MP-12已在美国获得兽医使用的有条件许可。MP-12表现出温度敏感(ts)表型,在41°C时不复制。ts突变限制了病毒在特定体温下的复制,可能导致病毒减毒。在此,我们将综述RNA病毒中特征明确的ts突变,并进一步讨论设计新型裂谷热减毒活疫苗的潜力。